Prospective Evaluation of First-Line Erlotinib in Advanced Non-Small Cell Lung Cancer (NSCLC) Carrying an Activating EGFR Mutation: A Multicenter Academic Phase II Study in Caucasian Patients (FIELT).

MLA

Jacques De Grève, et al. “Prospective Evaluation of First-Line Erlotinib in Advanced Non-Small Cell Lung Cancer (NSCLC) Carrying an Activating EGFR Mutation: A Multicenter Academic Phase II Study in Caucasian Patients (FIELT).” PLoS ONE, vol. 11, no. 3, Jan. 2016, p. e0147599. EBSCOhost, https://doi.org/10.1371/journal.pone.0147599.

APA

Jacques De Grève, Jan Van Meerbeeck, Johan F Vansteenkiste, Lore Decoster, Anne-Pascale Meert, Peter Vuylsteke, Christian Focan, Jean-Luc Canon, Yves Humblet, Guy Berchem, Benoit Colinet, Danny Galdermans, Lionel Bosquée, Joanna Vermeij, Alex Dewaele, Caroline Geers, Denis Schallier, & Erik Teugels. (2016). Prospective Evaluation of First-Line Erlotinib in Advanced Non-Small Cell Lung Cancer (NSCLC) Carrying an Activating EGFR Mutation: A Multicenter Academic Phase II Study in Caucasian Patients (FIELT). PLoS ONE, 11(3), e0147599. https://doi.org/10.1371/journal.pone.0147599

Chicago

Jacques De Grève, Jan Van Meerbeeck, Johan F Vansteenkiste, Lore Decoster, Anne-Pascale Meert, Peter Vuylsteke, Christian Focan, et al. 2016. “Prospective Evaluation of First-Line Erlotinib in Advanced Non-Small Cell Lung Cancer (NSCLC) Carrying an Activating EGFR Mutation: A Multicenter Academic Phase II Study in Caucasian Patients (FIELT).” PLoS ONE 11 (3): e0147599. doi:10.1371/journal.pone.0147599.